Melanoma Treatment
Melanoma Treatment
Treatment for melanoma follows two questions in order. The first is whether the melanoma is still confined to the skin, in which case removing it with an adequate margin is the treatment and the margin is set by the thickness. The second is what the tissue shows: whether the draining node contains melanoma, and whether a marker such as BRAF opens the way to targeted treatment. Immune checkpoint inhibitors and targeted combinations have largely displaced chemotherapy, and both are used after surgery for higher-risk melanoma and for disease that has spread.
The route at each stage
Melanoma treatment is unusually stage-driven: a small number of measurements separates an operation that is curative from a situation that needs drug treatment, and the same measurements decide how closely a person is followed afterwards.
| Situation | Main treatment | What is added |
|---|---|---|
| Melanoma in situ, and thin melanoma in the skin | Complete removal with a margin of normal skin chosen by the thickness | Skin surveillance afterwards, since a second primary melanoma is the main risk |
| Thicker melanoma still in the skin | Wider excision, with sentinel node biopsy where the thickness or ulceration warrants it | Discussion of treatment after surgery where the risk of recurrence is judged high, and a defined imaging schedule |
| Melanoma in the regional nodes, or in-transit deposits | Operation on the node basin — completion dissection, or therapeutic dissection where nodes are clinically involved | An immune checkpoint inhibitor, or a BRAF plus MEK combination where a BRAF change is present |
| Melanoma that has spread to another organ | Drug treatment: immune checkpoint inhibitors, or targeted treatment where a marker allows it | Local treatment for a specific deposit — radiosurgery for a few brain deposits, surgery or radiotherapy for a symptomatic one |
At the boundaries the detail matters: a melanoma 0.8 mm thick with ulceration and one without are treated differently, as are a single small deposit in one node and several nodes involved. This is why the plan is made from the pathology report rather than from the diagnosis.
Wide local excision: how much skin is taken, and why
The operation for a melanoma confined to the skin is a wide local excision — the melanoma site removed together with a margin of normal-looking skin, the margin chosen by the Breslow thickness. The reasoning is that melanoma can extend beyond the visible lesion in a way that cannot be seen:
| Thickness of the melanoma | Margin of normal skin around it |
|---|---|
| Melanoma in situ | About 5 mm |
| Up to 1.0 mm | About 1 cm |
| 1.01 to 2.0 mm | About 1 to 2 cm |
| More than 2.0 mm | About 2 cm |
The figures are a maximum rather than a requirement for every site, because a melanoma on the face, the ear, a finger or the sole may be removed with a narrower margin and closer follow-up in exchange. Reconstruction — direct closure, a graft or a flap — is planned as part of the same operation, and a graft can make the scar easier to mistake for the original lesion, which is why the reconstruction is recorded.
Operating on the lymph nodes
The nodes are handled in two distinct situations, and keeping them apart matters because the purpose of the operation differs:
- A positive sentinel node, with nodes that are not enlarged — two established options: completion lymph node dissection, which gives the most complete information, or close ultrasound surveillance with dissection reserved for a node that appears or enlarges.
- The choice turns on the trade-off — dissection removes tissue and carries a risk of lymphoedema, which is more likely in the groin than the armpit; that is why all nodes are no longer removed as a matter of course.
- A node that is enlarged and confirmed to contain melanoma — the operation becomes treatment rather than staging, and treatment after surgery is usually discussed at the same time.
- Where dissection is not done, a schedule replaces it — ultrasound of the basin at fixed intervals, with a defined route back to the team if a node changes.
Immune checkpoint inhibitors
Immune checkpoint inhibitors release the brakes on the immune response so that the immune system itself acts against the melanoma. They are the mainstay of drug treatment in this disease, given as an infusion on a defined schedule:
- An inhibitor of PD-1 — pembrolizumab or nivolumab on its own — is the usual treatment after surgery for stage III melanoma and one of the standard treatments for advanced disease.
- Adding an inhibitor of CTLA-4 — ipilimumab with a PD-1 inhibitor — produces a more powerful immune response in advanced disease and carries a higher rate of side effects.
- The complications are inflammation, not the effects of chemotherapy — rash, diarrhoea or blood in the stool, thyroid or pituitary inflammation with fatigue or headaches, lung inflammation with cough or breathlessness, and hepatitis.
- They can appear weeks after a dose and are usually reversible when treated early, which is why new symptoms are reported rather than kept for the next appointment, and why thyroid, liver and other blood tests are checked on a schedule.
Targeted treatment where the melanoma carries a BRAF change
Where the tissue test shows a BRAF change, a BRAF inhibitor combined with a MEK inhibitor becomes available, both taken as tablets, and the two are used together because blocking the pathway at two points works better and is tolerated better:
- It can shrink deposits quickly, which matters when a melanoma is growing or causing symptoms.
- The response is not permanent — the melanoma develops ways around the blockade, and the treatment is then changed, often to immune-based treatment; the sequencing of the two is discussed rather than decided one drug at a time.
- Fever and chills are common and are the most frequent reason a dose is adjusted; rash, joint pain, fatigue, sun sensitivity and a rise in blood pressure are also seen, and are managed by adjusting the dose rather than stopping treatment.
The place of chemotherapy
Chemotherapy has a much smaller role in melanoma than in many cancers, because immune and targeted treatments work better and are better tolerated for most people. It is not obsolete, and it is used in defined situations:
- Where immune and targeted treatment are not suitable or have stopped working — drugs such as dacarbazine, temozolomide, or carboplatin with paclitaxel.
- Where the melanoma needs to be slowed quickly and the other treatments are not available.
- The aim is usually control rather than shrinking the disease away, and it should be stated clearly so that the benefit can be weighed against nausea, fatigue, a fall in blood counts and the risk of infection.
Radiotherapy: where it is used in melanoma
Melanoma was long regarded as responding poorly to radiotherapy, and the modern position is more specific: it is used where its purpose is defined, and not as a routine part of treating the primary melanoma.
- Stereotactic radiosurgery to brain deposits — the most important current use: a small number of deposits can be treated with highly focused radiation, often without an operation.
- Palliative treatment of a deposit causing symptoms — pain in a bone, bleeding from a deposit in the skin or a mucosal surface, or pressure on a structure — often given together with drug treatment rather than instead of it.
- Selectively to a node basin after dissection, where the risk of return in that area is judged high, weighed against the effect on lymphoedema.
- To the primary site where it cannot be removed completely, most often a lentigo maligna melanoma on the face in an older person, or where an operation is not possible.
Melanoma that has spread: what treatment is aiming at
When melanoma has spread, treatment is planned around two questions: which drugs are likely to work, and whether any individual deposit needs treating in its own right. Both are answered from the tissue markers and the imaging, and both are reviewed as treatment proceeds:
- The drug choice follows the markers — a BRAF change opens targeted treatment; without one, immune checkpoint inhibitors are used, alone or as a PD-1 and CTLA-4 combination in selected situations.
- Local treatment of specific deposits retains a role — a single brain deposit may be removed or treated with radiosurgery, a deposit in the lung or soft tissue that is causing a problem may be operated on where the disease elsewhere is controlled.
- In-transit disease confined to a limb is treated with isolated limb perfusion or infusion, and injection of a lesion directly with a modified virus is used in selected cases.
- Symptom control is part of treatment rather than a last resort — pain, nausea, fatigue and the effect on sleep and mood can all be addressed.
How the plan is made and reviewed
The plan is put together by several disciplines at one meeting rather than through a series of separate appointments, because the measurements that decide treatment come from different places:
- The dermatologist or surgeon sets the excision margin and the reconstruction, and discusses the node staging.
- The pathologist provides thickness, ulceration, mitotic rate, margins and marker results, and reviews slides reported elsewhere.
- The medical oncologist decides whether treatment after surgery is worthwhile and, where disease has spread, which drug is used and in what order; the radiation oncologist advises on radiosurgery and palliative treatment.
- Nursing and rehabilitation carry what matters most day to day — wound and graft care, lymphoedema prevention, and teaching self-examination.
- Your priorities belong in the discussion — avoiding lymphoedema, keeping to a work schedule, or treating the disease as intensively as possible changes which of the defensible options is right.